Consensus Champions Oncology, Inc.

Equities

Delayed Nasdaq Other stock markets 10:24:41 2024-07-10 am EDT			5-day change	1st Jan Change
5.15 ^USD	+2.79%		+6.19%	-8.36%

Jun. 04	Champions Oncology, Inc and Medicines Discovery Catapult Forge Partnership to Accelerate Radiopharmaceutical Therapeutics Development	CI
Mar. 15	Tranche Update on Champions Oncology, Inc.'s Equity Buyback Plan announced on April 5, 2023.	CI

d2c34786cf.CURncSSkb1x_JcWU3EcEokvwVbPOo7El74oR_Ehz8zw.MQcqSX3DDSYRQZzslhNxlT-JIPH94e5rostSsiBLy3loJx8eV9M-LDxUnA~ca491da6423cc7e6dabba920679e601c

Craig-Hallum Downgrades Champions Oncology to Hold From Buy	Mar. 13	MT
Craig Hallum Trims Champions Oncology Price target to $9 From $10, Maintains Buy Rating	Dec. 13	MT
Roth MKM Adjusts Price Target on Champions Oncology to $7.50 From $9, Maintains Buy Rating	23-09-22	MT
Benchmark Company Downgrades Champions Oncology to Hold From Speculative Buy	23-03-16	MT
Craig Hallum Adjusts Champions Oncology Price Target to $10 From $12, Maintains Buy Rating	23-03-16	MT
CHAMPIONS ONCOLOGY : Roth Capital Adjusts Price Target on Champions Oncology to $16 From $13.50, Maintains Buy Rating	21-03-15	MT

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

5.01 USD

Average target price

6 USD

Spread / Average Target

+19.76%

High Price Target

6 USD

Spread / Highest target

+19.76%

Low Price Target

6 USD

Spread / Lowest Target

+19.76%